Co-Ultramicronized Palmitoylethanolamide/Luteolin-Induced Oligodendrocyte Precursor Cell Differentiation is

Laura Facci1, Massimo Barbierato1, Mariella Fusco2

  • 1Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.

Insights

Palmitoylethanolamide-luteolin (PEALut) enhances oligodendrocyte differentiation for multiple sclerosis treatment. This compound promotes myelin repair by modulating TAM receptor signaling and mTOR pathways.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) treatment faces challenges with remyelination failure, leading to neurodegeneration.
  • Endogenous remyelination strategies targeting oligodendrocytes are crucial for MS therapy.
  • Palmitoylethanolamide-luteolin (PEALut) previously showed potential in promoting oligodendrocyte precursor cell (OPC) maturation.

Purpose of the Study:

  • To investigate the role of TAM receptors in PEALut-induced OPC maturation.
  • To elucidate the signaling pathways involved in PEALut's pro-differentiation effects.

Main Methods:

  • Quantitative real-time PCR to analyze mRNA expression of TAM receptors (Tyro3, Axl, Mertk) and myelin proteins (MBP, CNPase).
  • Immunostaining to assess protein expression of CNPase and Tyro3.
  • Treatment of OPC cultures with PEALut, rapamycin (mTOR inhibitor), and vehicle control.

Main Results:

  • Tyro3 mRNA expression increased during OPC differentiation, mirroring myelin protein patterns.
  • PEALut significantly upregulated Tyro3 mRNA and downregulated Axl and Mertk mRNA in OPCs.
  • Rapamycin inhibited oligodendrocyte differentiation and myelination, but PEALut partially rescued these effects.
  • PEALut increased MBP and CNPase expression, indicating enhanced myelination.

Conclusions:

  • PEALut promotes oligodendrocyte differentiation and myelination, potentially via modulation of TAM receptor signaling.
  • The mammalian target of rapamycin (mTOR) pathway is implicated in PEALut's beneficial effects on myelination.
  • PEALut represents a promising therapeutic candidate for enhancing remyelination in multiple sclerosis.